Yeah, not going to respond in detail because I think we wholeheartedly disagree on almost every point.
There's just no such thing as a 'coin flip' meaningless marker with 99% predictive value and perfect experimental rigor. Not really how coins work.
As for the study (which I guess is the point), I touched lightly on my problems with it at first glance. They compare ME/CFS to healthy controls only. I see this a lot. Besides a very small sample size (50 patients), you really need a cohort of people with non-ME/CFS illnesses so you don't find you're classifying just the difference between sick and healthy. Ideally you'd need a significant sample size of healthy and some samples of different diseases - neurological, autoimmune, etc.
It seems they're trying to avoid overfitting, but when I see a 99% AUC with such a small sample set and a poorly chosen control, it seems very likely that it's still overfitting the data. The testing of 768 metabolites is quite interesting and the data aren't meaningless - just that I think the cohort design is a much bigger problem than the AI methodology (which at a quick glance seems pretty solid). I have no way to know if they are identifying metabolites of illness, or metabolites of ME/CFS.
That said, I think it's only appropriate to cite ChatGPT about the specific metabolites highlighted.
Insights into Disease Mechanisms
- Metabolic Dysfunction: The involvement of these specific metabolites suggests that metabolic dysfunction might play a role in ME/CFS. Each metabolite is involved in different biochemical pathways, indicating potentially complex and multifaceted metabolic irregularities in ME/CFS patients.
- Oleoylcholine: This compound could indicate alterations in lipid metabolism or signaling.
- Cortisone: As a glucocorticoid, cortisone is involved in stress response and immune function, hinting at potential dysregulation in these systems.
- 3-Hydroxydecanoate: This is a medium-chain fatty acid, potentially pointing to abnormalities in fatty acid metabolism.
- C-glycosyltryptophan: This is a modified amino acid, which could indicate changes in protein synthesis or degradation, or alterations in gut microbiota (as gut bacteria can modify tryptophan).
- Interconnected Pathways: These metabolites could be part of interconnected metabolic pathways that are disrupted in ME/CFS, suggesting a complex interplay of factors rather than a single causative agent.
- Potential Therapeutic Targets: Understanding the roles these metabolites play in ME/CFS could lead to targeted therapies that address these specific metabolic dysfunctions.
Limitations and Further Research
- Correlation vs. Causation: While these metabolites are correlated with ME/CFS, it's not clear whether they are a cause or an effect of the disease.
- Individual Variability: ME/CFS is a heterogeneous condition, and these metabolites might not be relevant for all patients.
- Need for More Research: Further studies are required to understand the exact roles of these metabolites in ME/CFS and how they interact with other factors like genetics, environment, and immune function.